Peficitinib

Peficitinib (brand name Smyraf) is a JAK inhibitor used mainly for treating rheumatoid arthritis (RA) in adults who haven’t responded well to conventional therapies, approved in Japan. It works by blocking Janus kinases, which interrupts inflammatory signals, helping reduce joint inflammation, destruction, and potentially improving bone quality in RA. While studied for other conditions like psoriasis and ulcerative colitis (UC), its main approved use is RA. It is grouped under the following drug class(es): Immunosuppressants, JAK inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-inflammatories and antirheumatic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include 4-((Trans-5-hydroxyadamantan-2-yl)amino)-1H-pyrrolo(2 and 3-b)pyridine-5-carboxamide. Its PubChem CID is 57928403.